Siste nytt innen Helse og Vaksiner!


You are here: Home / Top Picks / FDA Approves VAXELIS Combo Vaccine Despite Infant Mortality
Primary Sidebar

Watch Featured Video

Meet the Experts
Spotlight on Ty Bollinger, Host & Author

Top Picks of the Week
ancient nutrition ttac partnership
The Truth About Cancer forms Strategic Alliance with...
Read »
By Ty & Charlene Bollinger
6-in-1 vaxelis vaccine breaking news
FDA Approves VAXELIS Combo Vaccine Despite Infant...
Read »
By Ty Bollinger
pinterest censorship featured image
Pinterest, Freedom, and the Age of Tyrannical...
Read »
By Charlene Bollinger
turkey tail polypore
PSK: Popular Japanese Cancer Treatment STILL Not...
Read »
By Ty Bollinger
sugar and cancer growth
New Research Highlights Connection Between Sugar and...
Read »
By Ty Bollinger
Print this article
FDA Approves VAXELIS Combo Vaccine Despite Infant Mortality
By Ty Bollinger
15,116 Facebook Shares

6-in-1 vaxelis vaccine breaking news
Last week, the U.S. Food and Drug Administration (FDA) approved VAXELIS, a new 6-in-1 combo vaccine. The new drug, produced as a collaborative effort by pharmaceutical giants Merck and Sanofi, claims to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae (H. influenzae) type b.

The vaccine has been approved for infants as young as 6 weeks old and will be administered in a series of 3 doses between 6 weeks and 4 months of age.

As the vaccine schedule for children continues to inflate, we need to start asking better questions. Is this vaccine safe? Is it effective? Are developers adequately testing these drugs before going to market? At 6 weeks, are infants equipped to handle the increasing burden of vaccines being mandated by the Centers for Disease Control (CDC)?

Here’s what you need to know about the new combo drug: